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New Findings 
 
What is the central question of this study? Do the pulmonary vascular responses to 
hypoxia change during progressive exposure to high altitude and can alterations in these 
responses be related to changes in concentrations of circulating biomarkers that affect the 
pulmonary circulation. 
 
What are the main finding and its importance? In our field study with healthy 
volunteers, we demonstrate changes in pulmonary artery pressure suggestive of 
remodeling in the pulmonary circulation, but find no changes in the acute responsiveness 
of the pulmonary circulation to changes in oxygenation during two weeks of exposure to 
progressive hypoxia. Pulmonary artery pressure changes were associated with changes in 
erythropoietin, 8-isoprostane, nitrite and cGMP. 
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Abstract 
 
We sought to determine whether changes in pulmonary artery pressure responses to 
hypoxia suggestive of vascular remodeling occur during progressive exposure to high 
altitude and whether such alterations are related to changes in concentrations of 
circulating biomarkers with known or suspected actions on the pulmonary vasculature 
during ascent. We measured tricuspid valve transvalvular pressure gradients (TVPG) in 
healthy volunteers breathing air at sea level (London, UK) and under hypoxic conditions 
simulating the PIO2 at two locations in Nepal, Namche Bazaar (NB, elevation 3,500 m) 
and Everest Base Camp (EBC, elevation 5,300 m). During a subsequent thirteen day trek, 
TVPG was measured at NB and EBC while volunteers breathed air and hyperoxic or 
hypoxic mixtures simulating the PIO2 at the other locations. For each location, we 
determined the slope of the relationship between TVPG and arterial oxygen saturation 
(SaO2) to estimate the pulmonary vascular response to hypoxia. Mean TVPG breathing 
air was higher at any SaO2 at EBC than at sea level or NB, but there was no change in the 
slope of the relationship between  SaO2 and TVPG between locations. Nitric oxide 
availability remained unchanged despite increases in oxidative stress (elevated 8-
isoprostane). Erythropoietin, pro-ANP and IL-18 levels progressively increased on 
ascent. Associations with TVPG were only observed with erythropoietin, 8-isoprostane, 
nitrite and cGMP.  While the increased TVPG for any given SaO2 at EBC suggests 
pulmonary vascular remodeling may occur during 2 weeks of progressive hypoxia, the 
lack of change in the slope of the relationship between TVPG and  SaO2 indicates that the 
acute pulmonary vascular responsiveness to changes in oxygenation does not vary within 
this time frame. 
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Abbreviations: FIO2: inspired fraction of oxygen; HPV: hypoxic pulmonary 
vasoconstriction; IVC: inferior vena cava; PA: Pulmonary artery; PAO2: Alveolar partial 
pressure of oxygen; PVR: Pulmonary vascular resistance; RAP: right atrial pressure; 
SaO2: arterial oxygen saturation; TR: tricuspid regurgitation; TVPG: transvalvular 
pressure gradient;  
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Introduction 
 
Hypoxic pulmonary vasoconstriction (HPV) occurs in response to a decrease in the 
alveolar partial pressure of oxygen (PAO2) and serves to maintain adequate ventilation-
perfusion relationships and thereby preserve gas exchange in response to localized 
processes, such as pneumonia, that affect the lung in a heterogeneous manner. However, 
following ascent to high altitude, PAO2 is decreased throughout the lung (due to the fall in 
barometric pressure and therefore ambient PO2) leading to generalized HPV, which in 
conjunction with increased cardiac output, leads to a rise in pulmonary artery pressure. 
(Swenson, 2013)  
There are many well-understood features of this response. For example, it is known 
that the initial phase of HPV in humans occurs within minutes of exposure to hypoxia 
with a further increase continuing over the next 8 hours (Dorrington et al., 1997; Talbot 
et al., 2005) and that individual pulmonary artery pressure responses vary substantially in 
magnitude with some people demonstrating large responses that may predispose to 
complications when traveling at high altitude. (Grunig et al., 2000; Dehnert et al., 2005) 
There are several aspects of HPV, however, that are not well understood.  
First, it is unclear how the response changes over time with continued exposure to 
hypoxic conditions. In other words, as an individual acclimatizes to high altitude, are 
there changes in the magnitude of the acute pulmonary artery (PA) pressure response to 
hypoxia? Baggish et al. (Baggish et al., 2010) examined pulmonary artery pressure 
responses to hypoxia following acute chamber exposure to hypobaric hypoxia (PB ~ 460 
mmHg) and during exposure to terrestrial high altitude (PB ~ 460 mmHg) following 7 
days at moderate altitude (PB 548 mm Hg).  They noted much smaller increases in mean 
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PA pressure with exposure to hypobaric hypoxia following the extended period at 
moderate elevation (25 + 4 vs. 37 + 8 mmHg, P < 0.001). Ghofrani et al. (Ghofrani et al., 
2006) noted a lower PA systolic pressure (PASP) following an 8-day trek to Everest Base 
Camp (EBC; 27.1 mmHg (95% CI 24.1 – 30)) compared to that following acute exposure 
at sea level to inspired oxygen tensions simulating EBC (PIO2 70 mmHg; PASP  30.5 
mmHg (95% CI 26 – 35)). Other studies have also found evidence of changes in the 
pulmonary vasculature with more prolonged hypoxic exposures. Groves et al. (Groves et 
al., 1987) exposed healthy volunteers to steadily decreasing barometric pressure in a 
hypobaric chamber simulating an ascent of Mt. Everest over 40 days and noted that PA 
pressure and pulmonary vascular resistance remained above sea level baseline values 
when volunteers breathed 100% oxygen during the last 20 days of their time in the 
chamber.  However, the use of 100% oxygen breathing as a test to eliminate HPV as a 
contributor, may itself introduce other changes that confuse the issue, such as reduction 
of elevated high sympathetic nervous activation. (Hansen & Sander, 2003)      
Another unanswered question is whether observed changes in PA pressure with 
progressive ascent to high elevation can be related to changes in the plasma or exhaled 
breath concentrations of vasoactive substances (biomarkers) known to affect the 
pulmonary circulation. While these biomarker concentrations have been measured at final 
altitudes following ascent, only a few studies have examined how these concentrations 
change with progressive ascent and how such changes relate to changes in pulmonary 
artery pressure. Donnelly et al (Donnelly et al., 2011)  found that changes in exhaled 
nitric oxide did not correlate with PASP in an ascent to 5050 m. Mellor et al (Mellor et 
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al., 2014) studied trekkers at 3833, 4450 and 5129 m and showed that B-type natriuretic 
peptides (BNP) and cardiac troponin T elevations were correlated with PASP.   
Intended to address these questions, our study had two aims. First, recognizing that 
HPV demonstrates a dose-response relationship, whereby greater degrees of hypoxia are 
associated with greater rises in pulmonary artery pressure, we sought to determine 
whether the PA pressure responses over a range of hypoxic conditions also change 
following prolonged exposure to high altitude. We hypothesized that the slope of the 
dose-response relationship tested at several altitudes during a trek to the Everest Base 
Camp (EBC) in Nepal would decrease due to acclimatization or remodeling. Second, we 
sought to measure a much larger number of biomarkers known or suspected to affect the 
pulmonary circulation repeatedly during an ascent to high altitude and determine whether 
the observed changes in these biomarkers were associated with observed changes in 
resting PA pressure. We hypothesized that biomarkers related to nitric oxide metabolism, 
oxidative stress, and inflammation, as well as endothelin, natriuretic peptides and 
erythropoietin would be associated with the changes in PA pressure at altitude.        
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Methods 
Ethical Approval and Recruitment 
After obtaining approval from Research Ethics Committee at University College 
London, we recruited volunteers from a group of healthy individuals, aged 18-65 years, 
participating in Caudwell Xtreme Everest, an observational cohort investigating human 
adaptation to progressive environmental hypoxia during a trek to EBC. (Levett et al., 
2010)  In London, we screened 32 of the 198 participants in the larger study for the 
presence of tricuspid regurgitation (TR) using echocardiography (ACUSON Cypress 
Ultrasound System, Siemens, Munich, Germany). Individuals with measureable tricuspid 
regurgitation were eligible to participate and provided written informed consent, which 
conformed to the standards of the Declaration of Helsinki. 
 
Testing Protocol 
For each eligible volunteer, an additional set of at least 10 valid spectral waveforms 
for TR was measured while breathing ambient air. Volunteers then breathed two hypoxic 
gas mixtures designed to simulate the average inspired PO2 (PIO2) at locations where they 
would undergo further testing in Nepal, Namche Bazaar (NB; elevation 3,500 m, FIO2 
0.135) and EBC (elevation 5,300 m, FIO2 0.104, Table 1).  Gas mixtures were 
administered by tight-fitting mask with a Hans-Rudolph valve to prevent re-inhalation of 
expired air or entrainment of ambient air. Volunteers inhaled gas from a 120-L Douglas 
bag filled from an external tank containing the pre-specified gas concentration (BOC 
Medical Gases, Manchester, United Kingdom). Gas mixtures were administered in the 
same order to each volunteer.  
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While supine, volunteers breathed each gas mixture for 45 minutes with collection of 
spectral waveforms of TR during the last 15 minutes of each exposure. Arterial oxygen 
saturation (SaO2) was measured by pulse oximetry (Mini-Torr Plus ®, Smiths Medical 
UK, Kent United Kingdom) every minute, and average values were calculated for the 
entire 45-minute period and for the 15 minutes during which echocardiography 
measurements were made. Volunteers breathed ambient air for 10 minutes between gas 
exposures. 
In Nepal, all volunteers followed the same itinerary from the Lukla (elevation 2800 
m) to EBC (Figure 1). At NB, SaO2 was measured every 60 seconds for 5 minutes while 
supine, at rest and breathing ambient air. After measuring spectral waveforms of TR 
repeatedly over an additional 10-minute period breathing air, volunteers breathed a 
hyperoxic gas mixture simulating the PIO2 at sea level (FIO2 0.326) and then a hypoxic 
gas mixture simulating the PIO2 at EBC  (FIO2 0.16; Table 1). Volunteers breathed each 
mixture for 45 minutes with repeated measurements of the spectral waveforms of TR 
over the last 15 minutes of each exposure. Volunteers breathed ambient air for 5 minutes 
between mixtures.  
A similar protocol was employed at EBC. Echocardiography measurements were 
made with volunteers breathing ambient air, hyperoxic gas mixtures simulating the PIO2 
at sea level (FIO2 0.425), NB (FIO2 0.273), and a hypoxic gas mixture equivalent to the 
PIO2 at Camp 1 (elevation 5900 m) on Mt. Everest (FIO2 0.18) (Table 1).  
At NB and EBC, gas mixtures were administered in the same order to all volunteers. 
The apparatus for administering the gas mixtures, pulse oximeters and echocardiography 
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system were the same as used in London. All testing took place at least 3 hours following 
exercise to allow resolution of any exercise-induced changes in PA pressure. 
Due to time considerations, testing took place over a two-day period at each testing 
location. Testing occurred in NB on the third or fourth day of the trek while testing 
occurred at EBC on the twelfth or thirteenth day of the trek. Volunteers tested on Day 3 
at NB were tested on the Day 12 at EBC and those tested on the Day 4 at NB were tested 
on Day 13 at EBC. Testing took place at approximately the same time of day in each 
location to control for diurnal variations in physiologic responses. 
To minimize the effects of acclimatization to hypoxia, volunteers abstained from 
exposure to simulated or terrestrial high altitude for 3 months prior to departure for 
Nepal. Volunteers were not allowed to take prophylactic medications to prevent altitude 
illness and were treated for altitude illness according to standardized protocols. 
 
Echocardiography Measurements 
TR measurements were performed using two-dimensional and Doppler 
echocardiography. Data were obtained using an apical 4-chamber view or a modified 
parasternal short axis view that permitted visualization of the regurgitant jet across the 
tricuspid valve. The same sonographer, who was not blinded to the testing conditions, 
obtained all sea level and altitude measurements.  Data from all testing sessions were 
stored on external disks and transported to Seattle, Washington where an experienced 
sonographer blinded to the study conditions determined the peak TR velocities by 
identifying the highest coherent boundary of the spectral waves (Siemens Cypress 
Viewer, Siemens, Munich Germany).  
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The transvalvular pressure gradient (TVPG) was estimated using the simplified 
Bernoulli equation: TVPG = 4V2 where V is the peak TR jet velocity in m/sec. We chose 
to report the TVPG rather than right ventricular or PA systolic pressure because the latter 
measurements require an estimate of right atrial pressure and logistical factors prevented 
storage and transport of videos of respiratory variation in inferior vena cava (IVC) 
diameter necessary for estimation by the blinded observer. Reported values for TVPG are 
mean + SD of the highest 10 values obtained during each measurement period.  
 
Blood Collection and Biomarker Measurements 
Blood samples were collected from volunteers at each study location prior to the 
echocardiography protocol. All samples were drawn from the antecubital vein into EDTA 
containers (BD Vacutainer). Whole blood samples were centrifuged at 800 x g for 15 
minutes and the plasma separated. Plasma samples prepared in London were placed in -
40°C commercial cryostorage, while those samples prepared in Nepal were immediately 
frozen in 1 ml aliquots in liquid nitrogen and maintained at liquid nitrogen temperatures 
for the duration of the expedition including transport back to Kathmandu. Samples were 
transported from Kathmandu to London on dry ice and stored in -40°C commercial 
cryostorage until analysis.  
Nitric oxide metabolite concentrations were quantified immediately following 
thawing of frozen plasma aliquots in the presence of N-ethylmaleimide (NEM, in PBS; 
10 mM final concentration). To determine circulating S-nitrosothiol concentrations, 
aliquots of NEM-treated EDTA plasma were directly injected into a triiodide-containing 
reaction chamber, and the NO produced from the reduction of protein nitroso species was 
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quantified using gas phase chemiluminescence (CLD 77sp, EcoMedics); the difference in 
NO detected from untreated samples and aliquots subjected to pretreatment by mercuric 
chloride served to calculate the mercury-displaceable proportion of NO bound to thiols. 
(Rassaf et al., 2002) To determine nitrate and nitrite concentrations, NEM-treated 
samples were deproteinized with ice-cold methanol (1:1 v/v), cleared by centrifugation 
and subjected to analysis by high pressure liquid chromatography using a nitrite/nitrate 
analyzer (ENO20, Eicom). Samples were processed in a staggered manner to ensure 
reproducible processing times, with daily calibrations and internal quality controls. 
Reported values are corrected for background contaminant levels of nitrite and nitrate.  
Pro-atrial natriuretic peptide (pro-ANP 1-98) and brain natriuretic peptide fragment 
(NT-proBNP 8-29) concentrations were determined by commercial enzyme 
immunoassay kits (ALPCO Diagnostics, Salem, NH). Erythropoietin (EPO) and 
guanosine 3’,5’-cyclic monophosphate (cGMP) concentrations were measured by ELISA 
(Bender MedSystems GmbH, Vienna, Austria; R&D Systems, Abingdon, United 
Kingdom). Endothelin-1 was measured by enzyme immunoassay (Endothelin-1 kit, Enzo 
Life Sciences, Farmingdale, NY). 8-iso-prostaglandin F2α (8-isoprostane) was quantified 
using direct competitive enzyme immunoassay (Assay Designs, Ann Arbor, MI).  Plasma 
cytokines, including IL-1ß/IL-1ra, IL-6, IL-8, IL-18, macrophage migration inhibitory 
factor (MIF) and TNF-α were measured in a multiplexed fashion using a premixed 
human cytokine panel and xMAP technology (Bio-Plex ProTM and Bio-Plex 200, Bio-
Rad, Hemel Hempstead, Hertfordshire, UK).  
Biochemical data are only reported for 10 out of the 11 individuals who completed 
the study due to missing data in some of the markers. 
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Statistical Analysis 
 Data are presented as mean values (± the standard deviation), 95% confidence 
intervals and medians with interquartile ranges (IQR) where appropriate. Cytokine 
responses were skewed so were log transformed for analysis.  Given the multiple 
experimental conditions, linear regression models were used to assess the impact of each 
experimental condition on TVPG (location and simulated FIO2 conditions).  Repeated 
measures linear regression models using generalized estimating equations (GEE) were 
used to analyze the data.  GEE allowed us to address repeated measures and the 
associated within-individual correlation within the model while generating population 
and individual level slopes; this latter aspect of the model provides distinct advantages 
over repeated measures ANOVA.  The models were first formulated as follows: Y= β0 + 
β1(location), where Y equals TVPG in separate models with additional models including 
a second term [β2 (SaO2)].  An interaction term was used to assess where the relationship 
between oxygen saturation and location (surrogate for altitude) to test whether the slope 
of the relationship between SaO2 and TVPG differed by location.  Similar models were 
used to assess the differences with each experimental condition by location (Y = to 
oxygen saturation).   
Because hypoxic pulmonary vasoconstriction is thought to occur in response to 
changes in alveolar PO2, we originally intended for the exhaled PO2, a surrogate measure 
of the alveolar PO2, serve as β2. However, logistical considerations in Nepal prevented 
use of a breath-by-breath cardiopulmonary exercise system necessary to measure this 
parameter. We opted, therefore, to use arterial oxygen saturation (SaO2) as the surrogate 
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measure. We feel this is valid given that none of the volunteers had underlying lung 
disease or new respiratory issues during the trek that could lead to poor association of 
alveolar PO2 with SaO2. 
For assessments of the biomarker relationships to location, each analyte was 
modeled as the dependent variable with location as the independent variable.  For all 
models, standardized residuals were plotted to assess assumptions of linear models.  
Because of the concern that errors from the regression models did not have the same 
distribution across all observation points (heteroscedasticity), Huber/White-corrected 
standard errors were employed (White, 1980). Power calculations were not done because 
the number of volunteers was limited by logistical constraints of the Caudwell Xtreme 
Everest protocol. No adjustment was made for multiple comparisons.  A two-sided p-
value of ≤ 0.05 was determined to be significant.  Analyses were performed with Stata 
12.0 (StataCorp, College Station, TX).   
 
Results 
Eleven volunteers (8 men, 3 women, mean age 47 +12 years) completed the entire 
protocol.  Five volunteers met criteria for acute mountain sickness (AMS) at NB (defined 
as a Lake Louise Acute Mountain Sickness score > 3) and five volunteers met criteria at 
EBC. Only two met criteria for AMS at both locations.  All of the volunteers used non-
steroidal anti-inflammatory drugs or acetaminophen for various purposes at some point 
during their trek. These medications do not have an effect on pulmonary artery pressure. 
(Naeije et al., 1987) No volunteers used acetazolamide, dexamethasone, nifedipine or a 
phosphodiesterase inhibitor before testing was completed. No volunteers developed or 
required treatment for high altitude pulmonary edema or cerebral edema.  
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Table 2 displays the mean SaO2 and TVPG for all volunteers breathing ambient air at 
each location.  
Table 3 displays the mean SaO2 achieved during the time period when 
echocardiography was performed under each testing condition at each location. In 
general, the SaO2 achieved under each testing condition closely approximated that 
measured when volunteers breathed ambient air at the location the testing conditions 
were intended to simulate. The largest observed differences were seen with attempts to 
simulate NB conditions in London and attempts to simulate EBC conditions in both 
London and NB.  
Figure 2 displays the TVPG as a function of SaO2 for all volunteers at each testing 
location. Best-fit lines through each set of data points represent the dose response 
relationship between SaO2 and TVPG. There were no statistically significant differences 
in the slopes of the best-fit lines between London and EBC. The slope of the best-fit line 
in NB showed a significant difference relative to London (mean difference 0.15, 95% CI 
0.08 to 0.23, P< 0.001) and a non-significant difference relative to EBC (mean difference 
0.09, 95% CI -0.20 to -0.16, P=0.09). 
Table 4 displays the mean TVPG at each testing location for different SaO2. At 70%, 
80% and 90% SaO2, the mean TVPG was higher at EBC than at London or NB 
(p<0.001).  
Figure 3 displays the steady-state concentrations of relevant plasma biomarkers at the 
three testing locations. A similar profile of changes in response to environmental hypoxia 
as that reported for members of the Core Team of the 2007 Caudwell Xtreme Everest 
expedition(Levett et al., 2011) was seen in the participants of the current study.  Ascent 
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to EBC was accompanied by progressive elevation of circulating erythropoietin 
concentrations. Consistent with the notion of increased oxidative stress at high altitude, 8-
isoprostane concentrations were higher at NB and EBC than London, (P< 0.001 for both 
comparisons). Yet, this was likely not a consequence of local or generalized 
inflammation as evidenced by the lack of significant changes in IL-1ß/IL-1ra, IL-6, IL-8 
and TNF-α. Those alterations were accompanied by modest, non-significant increases in 
nitrite and nitrate concentrations at NB; while S-nitrosothiols were lower at NB than 
London (P=0.002). While mean plasma cGMP levels remained largely unchanged 
between testing locations the inter-individual variability in circulating cGMP 
concentrations was markedly reduced on ascent to EBC. Taken together, this data 
suggests that systemic nitric oxide (NO) availability was maintained irrespective of the 
degree of hypoxia. No statistically significant differences were observed in the 
concentrations of endothelin-1 and pro-BNP between testing locations whereas levels of 
pro-ANP, interleukin-18 (IL-18) and macrophage migration inhibitory factor (MIF) 
tended to be higher at NB and EBC compared to sea-level. 
Mean TVPG at rest at each location was also examined as a function of biomarker 
concentrations. Statistically significant associations were seen between TVPG and EPO, 
8-isoprostane, nitrite and cGMP concentrations but not with any of the other biomarkers 
(Table 5). Mechanistically, this pattern of associations confirms the dependence of PA 
pressure on environmental oxygen availability and suggests that TVPG is dependent, at 
least in part, on the degree of systemic oxidative stress and nitric oxide availability. 
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Discussion 
Our study is one of the first attempts to examine changes in pulmonary vascular 
responses to hypobaric hypoxia in a concentration-response manner during progressive 
exposure to high altitude and demonstrates two key findings: (1) the mean TVPG at any 
given SaO2 is higher after 12-13 days at high altitude than following acute exposure to 
hypoxia at sea-level or shorter duration of exposure at high altitude and (2) the dose 
response to hypoxia over a range from sea level to 5,300 m does not change with 12-13 
days of progressive ascent to high altitude.   Taken together, these findings suggest that 
while some hypoxic hypertensive remodeling may occur during this time frame, the 
pulmonary circulation still displays an undiminished sensitivity and response to acute 
changes in alveolar PO2 as indirectly reflected by the surrogate SaO2.    
 
Evidence of Time-Dependent Hypoxic Remodeling of the Human Pulmonary 
Circulation 
Our finding that TVPG is higher at any given SaO2 following a few-week stay at high 
altitude is similar to results demonstrated in previous studies measuring PA pressure 
responses to acute and sustained hypoxia.  In their simulated ascent of Mt. Everest over 
40 days, Groves et al. (Groves et al., 1987) noted a decrease in mean PA pressure when 
volunteers received supplemental oxygen (FIO2 = 1.0) at barometric pressures of 347, 282 
and 240 mm Hg, but the PA pressure at each time point remained above the mean PA 
pressure measured breathing ambient air at sea-level. Similarly, Maggiorini et al. 
(Maggiorini et al., 2001) found that PA pressure after several days at 4,559 m decreased 
in normal and HAPE-susceptible individuals following administration of an FIO2 1.0, but 
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remained higher than PA pressure measured breathing ambient air at 490 m prior to the 
ascent.  
The fact that TVPG or PA pressure does not return to sea-level values with inhalation 
of supplemental oxygen enough to recreate the sea level inspired PO2 suggests that 
pulmonary vascular remodeling may occur during prolonged hypoxic exposure at high 
altitude in the range of several days to weeks. With addition of supplemental oxygen, 
cardiac output declines to sea-level values (Groves et al., 1987; Maggiorini et al., 2001) 
and, as a result, any remaining increase in the TVPG or PA pressure would be expected 
to result from higher pulmonary vascular resistance (PVR). Given that supplemental 
oxygen should raise the PAO2 and eliminate HPV, this implies that other factors account 
for the higher PVR. We did not measure cardiac output and, as a result, cannot confirm 
that the higher TVPG is due to higher PVR rather than residual increases in cardiac 
output in our study, but Groves et al. (Groves et al., 1987) did measure cardiac output and 
found that PVR remained elevated despite supplemental oxygen.    
In considering these results further, both Groves et al. (Groves et al., 1987) and 
Maggiorini et al. (Maggiorini et al., 2001) administered an FIO2 of 1.0 to study 
participants at each barometric pressure whereas we administered only enough 
supplemental oxygen to raise the PIO2 to sea-level values. This is significant as an FIO2 of 
1.0 would raise PaO2 far higher than in our study and could alter sympathetic tone and 
other aspects of both left and right-sided hemodynamics in a different manner than that 
seen with our approach.  Because in both studies, cardiac output fell considerably with 
100% oxygen possibly as a result of withdrawal of sympathetic tone, (Hansen & Sander, 
2003) it is not possible to be certain that the lack of change in calculated PVR is 
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consistent with loss of HPV, even as early as several days at high altitude.  Ideally HPV 
would be better assessed by return of the subject to a normoxic arterial PO2 rather than a 
very hyperoxic PO2.  
Two studies (Dorrington et al., 1997; Fatemian et al., 2016) in which volunteers 
exposed to 8 hours of normobaric isocapnic hypoxia to maintain an end-tidal PO2 of 50 
mmHg (SaO2 of roughly of 80%) suggest an even shorter duration of time to initiate 
remodeling.  These two studies demonstrated that when subjects returned to breathing 
normal ambient sea-level air, their PA systolic pressure did not fall completely back to 
baseline.  This could be taken as evidence that even eight hours is sufficient to generate 
some remodeling. However, given that systemic blood pressure displays a diurnal 
variation with an increase from morning to afternoon/evening, what these authors found 
may have been simply a diurnal variation in PA pressures.  They did not examine this 
possibility by using a suitable control group not exposed to hypoxia over the same 
timeframe and in our search of the literature; we found no studies of the diurnal behavior 
of the pulmonary circulation in healthy subjects. 
Despite the fact that pulmonary vascular remodeling may occur after just a short time 
at high altitude, our data suggest that the acute pulmonary vascular responsiveness to 
changes in PAO2 is unchanged over at least the first several weeks at high altitude. This 
conclusion is based on the fact that the slope of the relationship TVPG and SaO2 was 
unchanged between EBC and London (Figure 2). There was a statistically significant 
difference in slope between London and NB but this was not robust to changes in 
parameterization and thus is not considered materially significant.  If the small 
differences we found in the slopes in NB and London were indicative of a changing 
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behavior of the pulmonary vasculature to longer duration hypoxia, we would predict an 
even greater difference between EBC and London.  This was not evident in our study. 
In support of our finding of preservation in responsiveness of the pulmonary 
circulation, Hilty et al. (Hilty et al., 2016) studied healthy volunteers by right heart 
catheterization after three weeks at 3600 m. They found that while PA pressures were 
mildly elevated, when the pulmonary circulation was challenged with a brief 2.5 l/min 
increase in cardiac output by transient thigh cuff occlusion there was no increase in PA 
pressure.   In this regard, our findings of maintained responsiveness to changes in 
inspired oxygen are similar and indicate that the pulmonary vascular pressures, while 
greater over this time, do not become permanently fixed at a higher resistance.  More 
work will be necessary to further delineate the time course and whether the rate of 
remodeling varies based on the duration of stay and rate of ascent at high altitude. 
The lack of change in pulmonary vascular responsiveness to changes in alveolar PO2 
as reflected by changes in SaO2 is different than we originally hypothesized based on data 
from Baggish et al., (Baggish et al., 2010) in which PA pressure at terrestrial 4,300 m 
was lower following a 6-day stay at an intermediate altitude (2,200 m) when compared to 
acute exposure to simulated 4,300 m.  We do not feel that their findings refute the 
observations in our study as our approach was different from that used in their 
investigation. Whereas Baggish et al. only estimated PA pressure breathing ambient air at 
4,300 m and, as a result, did not assess the dose response to hypoxia, we estimated TVPG 
under multiple conditions at the same elevation and, as a result, were better able to define 
the relationship. The differences in results between our studies may also be due to the fact 
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the volunteers in our study spent much longer time at high altitude than the volunteers 
examined by Baggish et al.  
 
Biomarker Measurements 
The mechanism by which preservation of acute pulmonary vascular responsiveness to 
hypoxia remains unchanged despite the fact that baseline pulmonary vascular resistance 
may be elevated because of hypoxic remodeling is unclear We measured various 
circulating mediators and biomarkers of pathways known to affect the pulmonary 
circulation to explore what vasoactive mediators and potential mechanisms may be 
involved. With the exception of EPO, 8-isoprostane, nitrite and cGMP, we did not find 
any statistically-significant associations between resting TVPG at each location and the 
concentration of the measured biomarkers.  These changes are consistent with the notion 
that human exposure to hypoxia alters systemic redox status towards a higher oxidative 
poise (indicated by increased levels of circulating lipid oxidation products such as 8-
isoprostanes) and that an elevation of nitric oxide production and availability (as reflected 
by enhanced plasma nitrite and cGMP levels) is important to allow adequate adjustment 
of pulmonary vascular tone to enable ventilation perfusion matching that is fit for 
purpose.  While we do observe changes in biomarkers of nitric oxide metabolism that are 
clearly known to affect PA pressure, more sophisticated measurements of production and 
consumption are needed to ascertain whether they are driving changes in TVPG and PA 
pressure in a fundamental manner.  
The association of EPO with HPV changes may not imply causality because EPO 
also rises with increasing altitude exposure as the kidneys themselves experience a fall in 
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their local PO2.  Furthermore, there are no data that EPO causes pulmonary 
vasoconstriction (Kuriyama et al., 2014; Berendsen et al., 2016).  Our failure to find any 
associations of the other chosen biomarkers with PA pressure changes may relate to the 
fact that other possibly relevant vasoactive mediators also known to alter HPV, such as 
several products of prostaglandin metabolism and microRNAs, might be more relevant. 
Another issue that may have affected the results is the fact that these biomarkers were 
assessed at each location while volunteers breathed ambient air prior to our testing 
protocol rather than during or shortly after breathing the different gas mixtures.  As a 
result, the measured circulating concentrations of these markers may not reflect the true 
plasma levels (or more relevant local tissue concentrations) during the different hypoxic 
or hyperoxic exposures, assuming that they would rapidly change in response to altered 
inspired oxygen concentration. Nevertheless, some of the changes observed are 
informative inasmuch as they document that neither circulating concentrations of 
endothelin nor the systemic availability of NO, both important modulators of pulmonary 
vascular tone, changed considerably during ascent. The latter is particularly remarkable 
in view of the oxidative stress that typically accompanies acute and chronic hypoxic 
exposures, as verified by the rise in circulating levels of the lipid oxidation product 8-
isoprostane, and is consistent with earlier observations. (Levett et al., 2011)   
Other biomarker changes are noteworthy in the context of the known association 
between pulmonary diseases and ventricular diastolic dysfunction. Consistent with a 
stimulation of ANP secretion as part of the normal acclimatization process to hypoxia, 
(Chen, 2005) we documented a trend towards higher plasma concentrations of pro-ANP 
at NB and EBC compared to sea level, with concomitant rises in IL-18 and MIF. The 
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latter is an oxygen-sensitive archetypical cytokine that has been proposed to mediate 
hypoxia-induced pulmonary hypertension (Zhang et al., 2012)  and also plays a role in 
several aspects of cardiovascular disease; (Zernecke et al., 2008) the former has been 
implicated in the diastolic dysfunction that results from global hypoxic vasoconstriction 
and consecutive increases in right ventricular afterload. (Larsen et al., 2008) While brain 
natriuretic peptide is often elevated with pulmonary hypertension, we found no changes 
in NT-BNP with time and increasing altitude.  Our findings are consistent of those with 
Toshner et al., (Toshner et al., 2008) but differ from Mellor et al. (Mellor et al., 2014) 
who reported increased concentrations in trekkers ascending to EBC.  To the best of our 
knowledge, ours is the first study to document variations in plasma concentrations of 
these cytokines and other modulators of pulmonary vascular tone in conjunction with a 
functional assessment of the pulmonary circulation at high altitude. We find variations in 
these biomarkers occur as part of the normal physiologic adaptation to reduced inspired 
oxygen concentrations in healthy individuals, but do not in any simple way appear to be 
linked to the pulmonary vascular response. 
 
Study Limitations 
Owing to the constraints of the study design with its strict continuous ascent profile, 
we recognize that a true steady-state was not likely achieved at each of the two high 
altitude test sites.  Thus other unmeasured effects of varying time, different individual 
rates of acclimatization, and differences in individual time-averaged hypoxia ‘dose’ could 
weaken our claim to have found no differences in the acute HPV responsiveness over this 
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altitude span.  These weaknesses would need to be addressed in a separate study allowing 
subjects to remain longer at each altitude and to vary the order of altitude exposure.    
Another limitation is the fact that we did not measure exhaled gas concentrations or 
arterial blood gases to determine the PaCO2 or estimate the PAO2. We originally intended 
to estimate PAO2 and PACO2 by measuring exhaled gas concentrations with the integrated 
gas sensors of a commercial breath-by-breath cardiopulmonary exercise system 
(Metamax 3b, Cortex, Leipzig, Germany), but logistical issues prevented use of the 
system during testing in Nepal and this plan was aborted. The lack of such data is 
potentially important for several reasons. Because PaCO2 affects pulmonary vascular tone 
(Balanos et al., 2003; Swenson, 2013), the lack of information on this parameter 
prevented us from controlling for the effect of inter-individual differences in ventilation 
that may have affected pulmonary vascular responses. Because PAO2 rather than the PaO2 
is the dominant stimulus for HPV, we cannot confirm that we achieved exactly similar 
alveolar oxygen tensions across volunteers under each testing condition and, therefore, 
achieved similar stimuli for changes in PA pressure. Instead, we used SaO2 as a surrogate 
measure. We lack information on the alveolar-arterial oxygen difference to know if 
similar SaO2 corresponded to similar PAO2, but the saturation data and the fact that all 
volunteers had no preexisting lung disease and no evidence of HAPE based on clinical 
assessment would suggest they had normal gas exchange and, as a result, the expected 
PAO2.  
While the SaO2 achieved under each testing condition generally approximated the 
SaO2 measured when volunteers breathed ambient air at the location the testing 
conditions were intended to simulate, differences were observed with attempts to 
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simulate NB conditions in London and attempts to simulate EBC conditions in both 
London and NB. Despite the measured differences in the average saturations under these 
conditions, we achieved a large enough spread between SaO2 at each testing location that 
it is still feasible to define and compare the slopes of the concentration response 
relationship between the TVPG and SaO2 between locations. 
Another limitation is that we did not measure right atrial pressure (RAP) and, as a 
result, report the TVPG rather than the PA pressure. While guidelines for estimating PA 
pressures recommend estimating RAP by assessing collapsibility of the IVC through the 
respiratory cycle (Rudski et al., 2010) many studies assume a normal value of 5 or 7 mm 
Hg in healthy individuals.  (Grunig et al., 2000; Maggiorini et al., 2006) Logistical issues 
prevented assessment of IVC collapsibility by our blinded observer upon completion of 
the study and we opted not to use the latter approach. We do not feel this limits the 
findings of the study, as the primary goal was to determine the concentration response 
relationship to hypoxia and, as a result, we are less dependent on the absolute pressure 
measurements and more interested in how pressures change in response to changes in 
oxygenation. Given that we were studying healthy euvolemic individuals at each testing 
location, we have no reason to suspect large differences in RAP that would have 
systematically affected this relationship. 
       Other confounding factors in assessing changes in pulmonary vasoreactivity to 
oxygen by changes in TVPG are the effect of cardiac output and changes in hematocrit 
(viscosity) (Grant & Canty, 1989; Hoffman, 2011).  We did not measure cardiac output, 
but data from many other studies show at rest that acclimatized volunteers have very little 
change (5-7% fall) in cardiac output up to altitudes of 6000 m and over the changes in 
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inspired oxygen fraction we tested. (Groves et al., 1987; Ghofrani et al., 2006) The 
impact on TVPG and, therefore, pulmonary artery systolic pressure (PASP) with these 
small changes in cardiac output would be to reduce PASP by about 2% (Grant & Canty, 
1989) and thus would not likely to have influenced our conclusions.   
The mean (and standard deviation) hematocrit of the volunteers was 44.1 % (+ 
1.7) in London, 46.7.1 % (+ 1.9) at NB, and 49.2 % (+ 2.2) at EBC.  These small 
differences between hematocrit at each location were statistically significant different 
from each other (p < 0.05).  The imprecision that the increases in hematocrit and 
viscosity from London to EBC adds to the tricuspid regurgitant velocity as a surrogate for 
pulmonary vascular resistance would be an approximate 3% underestimation of the true 
TVPG. (Cinar et al., 1999; Giardini, 2011; Hoffman, 2011)  Recalculating TVPG values 
taking the hematocrit changes into account did not change the slopes of the TVPG vs. 
SaO2 at each altitude shown in Figure 2.    
 
 
 
Conclusion 
This study of healthy trekkers traveling to 5,300 m in elevation demonstrated that the 
mean TVPG at any given SaO2 is higher after 12-13 days at high altitude than following 
acute exposure to hypoxia at sea-level or shorter duration of exposure at high altitude and 
that the slope of the relationship between TVPG and SaO2, reflective of the acute 
pulmonary vascular responsiveness to hypoxia, does not change over the first 12-13 days 
of progressive high altitude exposure. Further studies including estimates of cardiac 
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output and end-tidal CO2 tensions along with other vasoactive mediators not measured in 
this study are warranted to confirm these findings and further evaluate the time course 
and mechanisms of pulmonary vascular remodeling and acute responsiveness to oxygen 
with progressive hypoxic exposure. 
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Table 1: Estimated Inspired Gas Concentrations Used During Echocardiography 
Measurements at Each Testing Location 
 
Testing 
Location 
Altitude 
(m) 
Mean Barometric 
Pressure (mm Hg) 
Inspired Gas 
Concentrations 
Estimated PIO2 
(mm Hg) 
London 75 754 
0.210 149 
0.135 95 
0.104 74 
Namche 
Bazaar 
3500 505 
0.326 149 
0.210 96 
0.160 73 
Everest 
Base Camp 
5300 404 
0.425 152 
0.273 97 
0.210 75 
0.180 64 
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Table 2: Arterial Oxygen Saturation and Transvalvular Pressure Gradient 
Breathing Ambient Air at Each Testing Location 
 
Testing Location 
Mean SaO2 
(%, 95% CI of Mean) 
Mean Transvalvular 
Pressure Gradient 
(mm Hg, 95% CI of Mean) 
London 
96.6 
(95.9-97.3) 
21.5 
(19.8 to 23.3) 
Namche Bazaar 
87.3 
(86.0- 88.7) 
28.2 
(25.9 to 30.6) 
Everest Base 
Camp 
73.0 
(70.3-75.5) 
38.0 
(34.5 to 41.4) 
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Table 3: Mean Arterial Oxygen Saturation During Echocardiography 
Measurements at Each Testing Location 
 
Experimental 
Condition 
Testing 
Location 
Mean SaO2 
Under 
Experimental 
Condition (%) 
Mean Difference 
in SaO2 Relative 
To Ambient Air at 
Testing Location* 
95% CI of Mean 
Difference 
London  
London 96.9 N/A N/A 
 NB 97.0 0.46 ♯ 0.153 to 0.772  
EBC 96.6 .001 -0.161 to 0.164 
 
Namche 
Bazaar (NB) 
London 84.9 -2.46 ♯ -1.476 to -3.436 
NB 87.3 N/A N/A 
EBC 87.5 0.19 -0.413 to 0.798 
 
Everest Base 
Camp (EBC) 
London 67.4 -2.79 ♯ -1.937 to  -3.643 
NB 68.8  -4.05 ♯ -2.828 to -5.270  
EBC 72.9  N/A N/A 
* Mean differences are based on a repeated measures regression model that differs 
slightly from the actual mean values at each side based on differing numbers of 
experimental assessments at each site. Site measurements range from 5 (during ambient 
air measurements) to 15 (while breathing gas mixtures) saturation assessments under 
each experimental condition. ♯ P < 0.05 
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Table 4: Mean Transvalvular Pressure Gradient (TVPG) at Each Location For 
Different Arterial Oxygen Saturations 
 
Testing Location 
TVPG adjusted for 
SaO2 90% 
(Mean, 95% CI) 
TVPG adjusted for 
SaO2 80% 
(Mean, 95% CI) 
TVPG adjusted for 
SaO2 70% 
(Mean, 95% CI) 
London 25.4 (22.9 – 27.9) 29.4 (26.6 – 32.1) 33.6 (30.5 – 36.7) 
Namche 26.3 (23.4 – 29.2) 30.5 (26.8 – 34.2) 34.7 (30.5 – 38.9) 
EBC 29.4 (27.1 – 31.8) † 33.6 (30.7 – 36.5) 37.8 (34.5 – 40.1) 
† P< 0.001 when comparing EBC transvalvular pressure gradient to either London or 
Namche. Comparisons between London and Namche did not demonstrate statistically 
significant differences. 
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Table 5: Relationship Between Biomarkers and Mean Transvalvular Pressure Gradient 
(mm Hg) While Breathing Air at Each Location 
 
Cytokine Coefficient for 
estimated 
TVPG 
95% CI for 
Coefficient 
P value 
 
Hypoxia/Oxidative Stress 
Erythropoietin 
[mIU/mL] 
0.171 0.022 to 0.320 0.024 
8-isoprostanes 
[ng/mL] 
-0.284 -0.381 to -0.187 <0.001 
 
Endothelin/Natriuretic Peptides 
Endothelin-1 
[pg/mL] 
0.109 -0.019 to 0.236 0.095 
pro-ANP 
[nmol/mL] 
1.864 -0.718 to 4.447 0.157 
NT-BNP 
[nmol/mL] 
0.007 -0.005 to 0.0175 0.248 
 
Nitric Oxide Pathway 
Nitrite [µM] 
 
-24.88 -43.4 to -6.35 0.009 
Nitrate [µM] 
 
0.033 -0.053 to 0.120 0.456 
S-nitrosothiols 
[nM] 
0.080 -0.0284 to 0.188 0.148 
N-nitrosamines 
[nM] 
0.150 -0.255 to 0.556 0.417 
cGMP 
[pmol/mL] 
0.068 0.014 to 0.122 0.014 
 
Inflammatory Cascade 
IL-1β[pg/mL] -1.490 -17.813 to 14.833 0.858 
IL-1ra [pg/mL] -0.030 -0.094 to 0.033 0.344 
IL-6 [pg/mL] -0.540 -1.400 to 0.320 0.218 
IL-8 [pg/mL] -0.097 -0.390 to 0.195 0.513 
TNFα [pg/mL] -0.042 -0.236 to 0.152 0.633 
IL-18 [pg/mL] 0.075 -0.034 to 0.184 0.176 
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MIF [ng/mL] 0.0008 -0.0002 to 0.0019 0.126 
Note: Using a repeated measures GEE regression model, Mean Transvalvular Pressure 
Gradient was the independent variable with cytokine levels each at dependent variables. 
Coefficient interpretation: for every 1 mm Hg increase in mean TVPG estimate, the 
biomarker changed by its specific unit. Statistically significant associations are 
highlighted in bold text.  
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Figure Legends 
 
Figure 1. Ascent profile. All volunteers followed the same itinerary. Testing was 
performed on either the second or third day at Namche Bazaar and Everest Base Camp. 
 
Figure 2. The transvalvular pressure gradient (TVPG) as a function of SaO2 for all 
volunteers at London (black squares), Namche Bazaar (open diamonds) and Everest Base 
Camp (grey triangles). Best-fit lines are drawn through each set of data points and denote 
the concentration response relationship between SaO2 and the TVPG at each location. The 
mean slope and 95% confidence interval of the best fit lines for the relationship between 
transvalvular pressure gradient and arterial oxygen saturation at each location are as 
follows: London: 2.1 (1.5-2.6); Namche Bazaar: 2.2 (1.6-2.8); Everest Base Camp: 2.1 
(1.6-2.6). The slope represents the change in TVPG for a 5% decrease in oxygen 
saturation. 
 
Figure 3. Circulating biomarker concentrations at different testing locations. Hypoxia 
(erythropoietin; EPO) and oxidative stress (isoprostanes; 8-isoPGF2α) markers 
demonstrate robust increases upon ascent to Namche Bazaar (p < 0.05) and Everest Base 
Camp (EBC) compared to London (p < 0.001). The nitric oxide metabolites nitrite and 
nitrate increased slightly at Namche Bazaar and showed trends towards a decrease at 
EBC. Bioactive S-nitrosothiols decreased significantly at Namche Bazaar (p < 0.05) and 
recovered to near-basal levels at EBC (p < 0.05 vs. Namche Bazaar). Systemic NO 
availability (cyclic GMP concentrations) remained unchanged at all altitudes. Atrial 
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natriuretic peptide (proANP) remained unchanged at Namche Bazaar but increased 
modestly at EBC (n.s.). The proinflammatory cytokines IL-18 and MIF tended to 
increase upon ascent to EBC (p < 0.05 for MIF; n.s. for IL-18). Data are presented as 
mean ± SEM. (* p < 0.05 vs. London, ** p < 0.001, †
 
p < 0.05 vs. Namche Bazaar). 
 
 
 
 
 
 
 
 
 
